N/A N=40 Imaging Biomarkers for TMS Treatment of Depression
Depression
Primary: Depressive Symptoms at 4 Weeks — 15.6; 15.6 units on a scale — p=0.16
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=7 Imaging Study of the Lungs During an Allergic Asthma Attack
Asthma · Atopy
Primary: Percentage Change in the Ratio of Mean-normalized Perfusion Within Ventilation Defective Regions Relative to Outside — -17.8 percentage
N/A N=190 Effect of Probiotic on the Innate and Adaptive Host Response to Rhinovirus (EPIARR)
Common Cold
Primary: Interleukin-8 (IL-8) — 133; 122 pg/ml
Phase 2 N=60 BTI320 (SUGARDOWN®) on Post-Prandial Hyperglycaemia in Subjects With Pre-Diabetes
Pre-Diabetes
Primary: Change in Serum Fructosamine in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo — -5.2; -9.4; -8.8 umol/L — p=0.57
Phase 4 N=28 Comparative Study of the Efficacy of SARNA Sensitive Lotion for Treatment of Uremic Itch in Adult Hemodialysis Patients
Pruritis
Primary: Investigator Global Assessment — 2.63; 2.32 units on a scale
Phase 4 N=455 Long-acting Beta Agonist Step Down Study
Asthma
Primary: Treatment Failure — 38; 39; 45 participants
N/A N=42 Investigation of Ocular Signs & Symptoms in Wearers Fitted With Contact Lenses Following Digital Device Use
Visual Performance
Primary: Subjective Overall Comfort — 65.0; 53.6; 61.9 units on a scale
Phase 4 N=24 A Bioequivalence Study of Cefadroxil Film Coated Tablets After A Single Oral Dose Administration to Healthy Subjects
Infections, Urinary Tract
Primary: Maximal Measured Plasma Concentration (Cmax) After a Single Dose — 28.18; 29.20 Microgram per milliliter
Phase 2 N=7 Efficacy of Granulocyte Colony Stimulating Factor (GCSF) In Patients With Dystrophic Epidermolysis Bullosa
Dystrophic Epidermolysis Bullosa
Primary: Percent Change of Active Blisters and in Total Blister/Erosion Counts — -29.6 percent change — p=0.82
Phase 2 N=34 Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Malignant Pleural Effusion · Recurrent Non-small Cell Lung Cancer · Stage IIIB Non-small Cell Lung Cancer
Primary: Overall Response Rate (Complete and Partial Responses) as Assessed by RECIST Criteria — 11 Participants
N/A N=88 Postoperative Nausea and Vomiting: Ramosetron Plus Aprepitant vs Palonosetron Plus Aprepitant
Postoperative Nausea and Vomiting
Primary: The Incidence of Postoperative Nausea and Vomiting — 5; 18 Participants — p=<0.05
Phase 2 N=50 Laboratory Study of Cannabidiol on the Effects of Smoked Marijuana
Smoking, Marijuana
Primary: Mood Scale - Subscale 'Feeling High' — 4.35; 2.48; 0.39; 6.55 units on a scale VAS 1-100 mm
Phase 1 N=30 Bioavailability of Different Applications of Dabigatran in Healthy Volunteers
Healthy
Primary: AUC0-inf for Total Dabigatran — 599; 1050; 928 ng(nanogram)*h(hour)/mL(milliliter)
Phase 1 N=31 Mild, Moderate and Severe Renal Impairment Study
Gout
Primary: Maximum Observed Plasma Concentration (Cmax) — 25.6; 29.0; 38.2; 16.7 ng/mL
N/A N=240 PROTECT-PACE STUDY - The Protection of Left Ventricular Function During Right Ventricular Pacing
Left Ventricular Dysfunction
Primary: Change in Left Ventricular Ejection Fraction From Baseline to 2 Years (Intent to Treat Cohort). — -2.29; -3.43 percentage — p=0.4347